Pro zobrazení tohoto obsahu je třeba být přihlášen.
Categories for Uncategorized
CHANGE IN CLONE SIZE DOES NOT PREDICT RISK OF MAJOR ADVERSE VASCULAR EVENTS: RESULTS FROM THE INTERNATIONAL PNH REGISTRY
15 septembra, 2020 7:11 pmAuthor(s): Régis Peffault de Latour, Austin Kulasekararaj, Loree Larratt, et. al. EHA Library. Gustovic P. Jun 15, 2019; 267448; S865...
ABSENCE OF GPI-NEGATIVE CELLS AT DIAGNOSIS AND LOW NEUTROPHIL COUNT 2 MONTHS AFTER ATGAM BASED TREATMENT ARE ASSOCIATED WITH LOWER 6-MONTH RESPONSE RATE IN ADULTS WITH (VERY) SEVERE APLASTIC ANEMIA
15 septembra, 2020 7:11 pmAuthor(s): Jennifer Tjon, Lisette Bogers, Liesbeth de Wreede, et. al. EHA Library. Tjon J. Jun 15, 2019; 266738; PS1121 ...
INHIBITION OF C3 WITH APL-2 CONTROLS HAEMOLYSIS AND INCREASES HAEMOGLOBIN LEVELS IN SUBJECTS WITH AUTOIMMUNE HAEMOLYTIC ANAEMIA (AIHA)
15 septembra, 2020 7:11 pmAuthor(s): Morie Gertz, Eloy Roman, Bruno Fattizzo, et. al. EHA Library. Fattizzo B. Jun 15, 2019; 267482; S899 Abstract:...
A PHASE 2 OPEN-LABEL PROOF OF CONCEPT STUDY OF THE ORAL, SMALL MOLECULE FACTOR D INHIBITOR, ACH-4471, IN UNTREATED PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
15 septembra, 2020 7:11 pmAuthor(s): Peter Browett, Austin Kulasekararaj, Jong Wook Lee, et. al. EHA Library. Browett P. Jun 15, 2019; 267447; S864 ...
ANÉMIE – NOVINKY Z KONGRESU EHA©
15 septembra, 2020 7:11 pmV Amsterdame sa v dňoch 13. – 16. júna 2019 uskutočnilo stretnutie viac ako 12 000 hematológov a iných odborníkov na 24. ročníku kongresu...
PET AFTER 2 CYCLES OF ABVD IN PATIENTS WITH EARLY-STAGE FAVORABLE HODGKIN LYMPHOMA TREATED WITHIN THE PHASE 3 GHSG HD16 STUDY
15 septembra, 2020 7:11 pmAuthor(s): Michael Fuchs, Helen Goergen, Carsten Kobe, et. al. EHA Library. Fuchs M. Jun 15, 2019; 267402; S819 Abstract:...
FIVE-YEAR FOLLOW-UP OF PATIENTS RECEIVING IBRUTINIB FOR FIRST-LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
15 septembra, 2020 7:11 pmAuthor(s): Alessandra Tedeschi, Jan Burger, Paul M. Barr, et. al. EHA Library. Tedeschi A. Jun 14, 2019; 267308; S107 ...
THE BRAF INHIBITOR VEMURAFENIB COMBINED WITH RITUXIMAB PRODUCES A HIGH RATE OF DEEP AND DURABLE REMISSIONS IN RELAPSED OR REFRACTORY HAIRY CELL LEUKEMIA: UPDATED RESULTS OF A PHASE-2 TRIAL
15 septembra, 2020 7:11 pmAuthor(s): Enrico Tiacci, Luca De Carolis, Edoardo Simonetti, et. al. EHA Library. Tiacci E. Jun 14, 2019; 267305; S104 ...
OBINUTUZUMAB PLUS DHAP FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION PLUS OBINUTUZUMAB MAINTENANCE PROVIDES A HIGH MRD RESPONSE RATE IN UNTREATED MCL PATIENTS, LYMA-101 TRIAL – A LYSA TRIAL
15 septembra, 2020 7:11 pmAuthor(s): S Legouill, Asma Beldi-Ferchiou, Victoria Cacheux, et. al. EHA Library. Le Gouill S. Jun 14, 2019; 267304; S103 ...
BLINATUMOMAB FOR MINIMAL RESIDUAL DISEASE (MRD) IN ADULTS WITH BCELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (BCPALL): MEDIAN OVERALL SURVIVAL (OS) NOT REACHED AT 5 YEARS FOR COMPLETE MRD RESPONDERS
15 septembra, 2020 7:11 pmAuthor(s): Nicola Goekbuget, Hervé Dombret, Gerhard Zugmaier, et. al. EHA Library. Goekbuget N. Jun 16, 2019; 267373; S1619 Abstract:...